



Opinion

A protocol of drug and infusion fluid: Preparation, administration, compatibility and stability in neonatal intensive unit care

Ebtisam Dribika, Nabila Hashad*, Rouwaida Ramadan, Fatma S. Ertemi

Neonatal Intensive Care Unit, Aljala Maternity and Gynecology Hospital, Ministry of Health, Tripoli, Libya

*Corresponding author: hashadnabila9@gmail.com

<https://orcid.org/0000-0001-7393-0290>

Received: 18-04-2022, Revised: 22-05-2022, Accepted: 08-06-2022, Published: 30-06-2022

Copyright © 2022 Dribika et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

HOW TO CITE THIS

Dribika et al (2022) A protocol of drug and infusion fluid: Preparation, administration, compatibility and stability in neonatal in intensive care unit. *Mediterr J Pharm Pharm Sci.* 2 (2): 3 - 6. <https://doi.org/10.5281/zenodo.6780436>.

Keywords: Administration, dosage form, formulation, medication error, newborn, neonates, NICU

Newborn or neonate denotes to an infant in the first few days after birth. They are not small children when it comes to medicinal use and formulation development. Neonates include term, post-term and preterm babies. The neonatal period for preterm newborn infants is defined as the day of birth through to the expected date of delivery plus 27 days [1]. The majority of drugs used in sick newborns receiving intensive care are unlicensed and off-label, exposing infants to a greater risk of adverse drug reactions (ADRs). This study is extremely important due to the presence of a variety of drug information sources if used together lead to medication errors. From this point of view, this approach is suggested to eliminate or minimize these varieties. Where the most important challenges in neonatal intensive care unit (NICU) is proper and correct calculations and administration. Drug-related events in a hospital setting are the highest cause of recorded errors such as in the USA and UK [2]. However, there are a wide range of potential sources of drug errors including documentation, calculation, preparation and administration [3]. Now, babies commonly receive off-label drugs, at dosages extrapolated

from children or adults. Besides the lack of labelling, inappropriate formulations, polypharmacy, immature organ function and multiple illnesses further raise the risk for ADRs in neonates [2].

Determining the right dose for drugs used to treat neonates is critically important. Neonates have significant differences in physiology affecting drug absorption, distribution, metabolism and elimination that makes extrapolating dosages from adults and older children are usually inappropriate [4]. Many neonatal patients in a critical care setting receive between 15 and 20 infusion (iv) medications daily. The majority of these are unlicensed or used off label. Lack of knowledge around the physicochemical incompatibilities of infusion drugs in NICU and PICU settings often necessitates the use of a dedicated iv catheter in neonates and infants who have limited IV access [5 - 7]. Drug incompatibilities are often an under-estimated aspect of clinical practice and are concerning in the neonatal population where a lower capability to compensate for ADRs may lead to higher morbidity and death [2, 6, 7]. This concern is exacerbated in neonates by the frequent requirements for poly-

pharmacy, multiple infusions delivered through a single catheter due to limited vascular access, low infusion rate exposing drugs to longer interaction and the possibility of incomplete dissolution or precipitation of drug due to low volumes of drug solutions. Realistically, limited venous access can result in little choice but to co-administer drugs [1].

Therefore, the aim of this study is to recommend and use local guidelines by which will decrease and minimize medication use errors and make the use of medication easier in NICU with improve the quality of baby's life by using proper preparations and cautions drug intake.

	Maintenance	Deficit
Kcl 15% 1 mmol = 0.50 cc	M = 1 - 2 mmol per kg Rate = 150 cc/kg/day, 1 mmol = 0.5 cc/kg/day, bottle = 500 cc $\frac{0.5 \times 500}{150} = 1.6$ cc kcl added to fluid bottle	Kcl daily requirement = M (maintenance) + D (deficit) $D = \frac{(4 - K \text{ reading}) \times wt \times 0.6}{2}$ = volume by cc Kcl 15% volume added to bottle = $\frac{(M + D) \times 500}{}$ Fluid daily requirement (rate x 24)
Kcl 10% 1 mmol = 0.74 cc	M = 1 - 2 mmol per kg Rate = 150 cc/kg/day, 1 mmol = 0.74 cc/kg/day, bottle = 500 cc $\frac{0.74 \times 500}{150} = 2.4$ cc kcl added to fluid bottle	Kcl daily requirement = M (maintenance) + D (deficit) $D = (4 - K \text{ reading}) \times wt \times 0.6 \times 0.74$ = volume cc KCL 10% volume added to bottle = $\frac{(M + D) \times 500}{}$ Fluid daily requirement (rate x 24)
Kcl 7.5% 1 mmol = 1.00 cc	M = 1 - 2 mmol per kg Rate = 150 cc/kg/day, 1 mmol = 1 cc/kg/day, bottle = 500 cc $1 \times 500 = 3.3$ cc Kcl added to fluid bottle	Kcl daily requirement = M (maintenance) + D (deficit) $D = (4 - K \text{ reading}) \times wt \times 0.6$ = volume by cc Kcl 7.5% volume added to bottle = $\frac{(M + D) \times 500}{}$ Fluid daily requirement (rate x 24)

The presence of different doses and precaution for calcium, Ca gluconate 10%, 1 mmol per kg = 4.4 cc/kg/day, 2 mmol per kg = 8.8 cc/kg/day. Ca chloride 10%, 1 mmol/kg/day = 1.5 cc/kg/day, 2 mmol/kg/day = 3.0 cc/kg/day. SLOW I.V WITHIN 30 MIN.

Table 1: Infusion drugs and infusion fluid compatibility common used in neonatal ICU

	dopamine	dobutamine	midazolam	NAHCO3	INSULIN	PROSTINE VR	ADRENALINE	Mgso4	thiopental	D5%	D10%	NS	D/AA
DOPMINE	Compatible	Compatible	Compatible	Not compatible	Not compatible	Compatible	Compatible	Compatible	Not compatible	Compatible	Compatible	Compatible	Compatible
dobutamine	Compatible	Compatible	Compatible	Not compatible	Compatible	Compatible	Compatible	Compatible	Not compatible	Compatible	Compatible	Compatible	Compatible
midazolam	Compatible	Compatible	Compatible	Not compatible	Compatible	Compatible	Compatible	Compatible	Not compatible	Compatible	Compatible	Compatible	Not compatible
NAHCO3	Not compatible	Not compatible	Not compatible	Compatible	Compatible	Compatible	Not compatible	Not compatible	Not compatible	Compatible	Compatible	Compatible	Not compatible
PROSTINEVR	Compatible	Not compatible	Compatible	Compatible	Compatible	Compatible							
ADRENALINE	Compatible	Compatible	Compatible	Not compatible	Compatible	Compatible	Compatible	Compatible	Not compatible	Compatible	Compatible	Compatible	Compatible
Mgso4	Compatible	Compatible	Compatible	Not compatible	Compatible	Compatible	Compatible	Compatible	Not compatible	Compatible	Compatible	Compatible	Compatible
THIOPENTAL	Not compatible	Compatible	Not compatible	Not compatible	Not compatible	Not compatible							
insulin	Not compatible	Compatible	Not compatible	Compatible	Compatible	Compatible	Compatible	Compatible	Not compatible	Compatible	Compatible	Compatible	Compatible

Compatible

Not compatible

No available information


DAA DEXTROSE AMINO ACID

Some drugs like vancomycin had acute side effect (red man syndrome). So, it should be given by correct infusion rate. Vancomycin 500 mg: Add 10 ml of water to drug vial, then calculate the dose by

ml as follows: Dose in the file multiple by 10 and divided by 500. The calculated dose by ml completed by normal saline according to body weight of the baby as in following table:

Total volume	Weight (kg)	Rate
06 cc	(1.7 to 2.0 kg)	06 cc /hr
08 cc	(2.1 to 2.5 kg)	08 cc /hr
09 cc	(2.6 to 3.0 kg)	09 cc /hr
11 cc	(3.1 to 3.5 kg)	11 cc /hr
13 cc	(3.6 to 4.0 kg)	13 cc /hr
14 cc	(4.1 to 4.5 kg)	14 cc /hr
16 cc	(4.6 to 5.0 kg)	16 cc /hr

Finally, but it is not the end, in this approach the calculations of iv infusion drugs are available in the following **Figure**



Conclusion: The present study suggests protocol (procedure) for drugs and infusion fluids used in the neonatal ICU of Algala Maternity Hospital, Tripoli, Libya. These plans are taken to facilitate the daily hard work, and to make it easier as well as more accurate. However, an absence of these

materials will lead to confusion, misunderstanding and misuse of drugs with failure of all the treatment process or protocols. Thus, a recommendation is provided to make sure that there should be a plan like this for drugs used in neonates in each unit of pediatric hospitals in Libya.

Author contribution: All the authors substantially contributed to the conception, compilation of data, checking and approving the final version of the manuscript, and agreed to be accountable for its contents.

Conflict of interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Data availability statement: The raw data that support the findings of this article are available from the corresponding author upon reasonable request.

Ethical issues: Including plagiarism, informed consent, data fabrication or falsification and double publication or submission have completely been observed by authors.

Author declaration: The authors confirm all relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.

References

1. O'Brien F, Clapham D, Krysiak K, Batchelor H, Field P, Caivano G, Pertile M, Nunn A, Tuleu C (2019) Making medicines baby size: the challenges in bridging the formulation gap in neonatal medicine. *International Journal of Molecular Sciences*. 20 (11): 2688. doi: 10.3390/ijms20112688.
2. Allegaert K, van den Anker JN (2015) Adverse drug reactions in neonates and infants: a population-tailored approach is needed. *British Journal of Clinical Pharmacology*. 80 (4): 788-795. doi: 10.1111/bcp.12430.
3. Emmerson AJ, Roberts SA (2013) Rounding of birth weights in a neonatal intensive care unit over 20 years: an analysis of a large cohort study. *British Medical Journal Open*. 3 (12): e003650. doi: 10.1136/bmjopen-2013-003650.
4. Ku LC, Smith PB (2015) Dosing in neonates: Special considerations in physiology and trial design. *Pediatric Research*. 77 (1-1): 2-9. doi: 10.1038/pr.2014.143.
5. British National Formulary (2007) BNF 54. Royal Pharmaceutical Society of Great Britain. BMJ London, UK. ISBN: 9780853697367.
6. Young TE (2011) NeoFax 2011. 24th Edition. Publisher: Physician's Desk Reference (PDR). pp. 350. NJ, United States. ISBN: 13 9781563637896.
7. Perkin RM, Swift JD, Newton DA, Anas NG (2008) *Pediatric Hospital Medicine: Textbook of inpatient management*. Walter Kluwer, Health. Lippincott Williams & Wilkins (LWW). pp. 924. Second edition. Orange, California, USA. ISBN: 978-0-78-177032-3.